|
|
|
Corporate Profile: ImClone
| Summary: |
ImClone is
a biopharmaceutical company dedicated to the development
of novel treatments for cancer and cancer-related
disorders. |
| Address (HQ):
|
180 Varick Street
New York, NY 10014 |
440 Route 22 East
Bridgewater, NJ 08807 |
| Phone #'s (HQ): |
Main |
(212) 645-1405 |
(908) 541-8100 |
| Human Resources |
not known |
not known |
| Investor Relations |
(646) 638-5058 |
not known |
| Fax #'s (HQ): |
Main |
(212) 645-2054 |
not known |
| Human Resources |
not known |
not known |
| Investor Relations |
(212) 645-2054 |
not known |
| email: |
Main |
not known |
not known |
| Human Resources |
not known |
not known |
| Investor Relations |
ir@imclone.com |
not known |
| Financial
information: |
| ImClone was aquired by Eli Lilly in 2008 |
| Number
of employees: |
| not known |
| Issued United States patents: |
Issued U.S. patents 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
